The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-29. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== See also == Glycogen storage disease Hitting the wall (muscle fatigue due to glycogen depletion) Inborn errors of carbohydrate metabolism Purine nucleotide cycle§Glycogenoses (GSDs) Second wind (increased ATP production primarily by fatty acids after glycogen depletion)
The World Health Organization estimates that tobacco causes 8 million deaths each year as of 2019 and ultimately caused 100 million deaths over the course of the 20th century. Cigarettes produce an aerosol containing over 4,000 chemical compounds, including nicotine, carbon monoxide, acrolein, and oxidant substances. Over 70 of these are carcinogens. The most important chemical compounds causing cancer are those that produce DNA damage since such damage appears to be the primary underlying cause of cancer. Cigarette smoking results in oxidative stress and oxidative DNA damage. DNA damage can be estimated by measuring urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and 8-oxoguanine DNA glycosylase (OGG1). DNA damage was found in a population study to be significantly increased in 250 cigarette smokers compared to 200 non-cigarette smokers. Cunningham et al. combined the microgram weight of each compound in the smoke of one cigarette with the known genotoxic effect of that compound per microgram to identify the most carcinogenic compounds in cigarette smoke. The seven most important carcinogens in tobacco smoke are shown in the table below, along with the DNA alterations they cause.
Affinity chromatography is a method of separating a biomolecule from a mixture, based on a highly specific macromolecular binding interaction between the biomolecule and another substance. The specific type of binding interaction depends on the biomolecule of interest; antigen and antibody, enzyme and substrate, receptor and ligand, or protein and nucleic acid binding interactions are frequently exploited for isolation of various biomolecules. Affinity chromatography is useful for its high selectivity and resolution of separation, compared to other chromatographic methods.
Together, they manage to get the increasingly aggressive U-Haul out of the house. Demon, still addicted to opioids, takes on and loses several minimum wage jobs but also reconnects with Tommy. Hanging out at the newspaper Tommy works for, Demon begins anonymously publishing a popular comic strip. Dori reveals that she is pregnant, and Demon tries to convince her to get sober for the baby. However, Demon comes home to find that Dori has miscarried, devastating them both. Dori's drug habit gets worse, culminating in a fatal overdose. Demon moves in with Maggot, both of them rattled over Emmy’s abuse and Dori’s death. Rose tells Demon and Maggot they can find Fast Forward by the waterfall at the Devil's Bathtub where Demon’s father died. On the way there, they pass Hammer Kelly, who is fixing a flat tire in the pouring rain. Heartbroken over Emmy, he has started doing drugs. He joins them as they head to seek justice, deciding to bring his rifle. Fast Forward, who is preparing for a reckless dive into the waterfall, fatally falls when he sees Hammer aiming the rifle at him. Hammer tries to save Fast Forward but drowns in the process. June sponsors a grief stricken Demon to stay at a rehab center in Knoxville. Here, Demon resumes drawing and decides to make a graphic novel about the history of the Appalachian people. Maggot has gone to juvenile prison for supplying Hammer with drugs the night he died, and Tommy has moved to Pennsylvania to marry a girlfriend he met online. Demon stays in touch with Angus, now at college in Nashville, and develops feelings for her.
==== Kinetics of antibody response ==== Humoral responses after a single DNA injection can be much longer-lived than after a single injection with a recombinant protein. Antibody responses against hepatitis B virus (HBV) envelope protein (HBsAg) have been sustained for up to 74 weeks without boost, while lifelong maintenance of protective response to influenza haemagglutinin was demonstrated in mice after gene gun delivery. Antibody-secreting cells (ASC) migrate to the bone marrow and spleen for long-term antibody production, and generally localise there after one year. Comparisons of antibody responses generated by natural (viral) infection, immunization with recombinant protein and immunization with pDNA are summarised in Table 4. DNA-raised antibody responses rise much more slowly than when natural infection or recombinant protein immunization occurs. As many as 12 weeks may be required to reach peak titres in mice, although boosting can decrease the interval. This response is probably due to the low levels of antigen expressed over several weeks, which supports both primary and secondary phases of antibody response. DNA vaccine expressing HBV small and middle envelope protein was injected into adults with chronic hepatitis. The vaccine resulted in specific interferon gamma cell production. Also specific T-cells for middle envelop proteins antigens were developed. The immune response of the patients was not robust enough to control HBV infection
Sources: en.wikipedia.org
Misuse by injection or use in the nose still occurs, and more recently the efficacy of naloxone in preventing misuse by injection has been brought into question and preparations including naloxone could even be less safe than preparations containing solely buprenorphine. Rates of misuse in the U.S. appear to be lower than with other opioids. The combination formulation was approved for medical use in the US in 2002, and in the European Union in 2017. A generic version was approved in the US in 2018. In 2019, it was the 272nd most commonly prescribed medication in the US, with more than 1 million prescriptions.
=== Hierarchical structure === While the secondary structures are determined by energy state and hydrogen bonds formed between amino acids, hierarchical structures are determined by the hydrophobicity of the peptide. Exon 1 encoded peptide is mainly hydrophilic, and is more extended when immersed in water. In contrast, exon 3 encoded peptide contains both hydrophobic and hydrophilic blocks, suggesting the formation of micelles, where the hydrophobic block will cluster on the inside with the hydrophilic portion surrounding it. Thus, a single complete resilin protein, when immersed in water, takes on the structure in which exon 1 encoded segment extends out from the micelle exon 3 encoded peptide forms. Once resilin is transferred to the outside of the cell, their exon 2 encoded peptides, the chitin binding segments, bind to chitin. Meanwhile, di- or tri-tyrosine crosslinking is formed by oxidative coupling, mediated by peroxidase, between tyrosine residuals. Like other elastomeric proteins, the degree of cross linking in resilin is low, which ensures the low stiffness and high resilience. Cross linked peptides encoded by exon 1 have a resilience greater than 93%, while that encoded by exon 3 has a resilience of 86%. In addition, natural resilin has a resilience of 92%, similar to that of exon 1, suggesting again that exon 1 may play a more important role in the elastic property of resilin.
==== Role of dopamine and glutamate ==== Dopamine is the primary neurotransmitter of the brain's reward system, and also has roles in movement, emotion, cognition and motivation. Natural rewards such as eating, and recreational drug use, both trigger dopamine release, which underlies their reinforcing quality. Excessive intake of many types of addictive drugs results in repeated release of high amounts of dopamine, which in turn affects the reward pathway directly through heightened dopamine receptor activation. Prolonged and abnormally high levels of dopamine in the synaptic cleft can induce receptor downregulation in the neural pathway. Downregulation of mesolimbic dopamine receptors can result in a decrease in the sensitivity to natural reinforcers. Drug seeking is driven by glutamatergic projections from the prefrontal cortex to the nucleus accumbens, and chronic drug exposure produces lasting glutamate-mediated changes along this route.
== Alanine world hypothesis == Alanine is one of the twenty canonical α-amino acids used as building blocks (monomers) for the ribosome-mediated biosynthesis of proteins. Alanine is believed to be one of the earliest amino acids to be included in the genetic code standard repertoire. On the basis of this fact the "alanine world" hypothesis was proposed. This hypothesis explains the evolutionary choice of amino acids in the repertoire of the genetic code from a chemical point of view. In this model the selection of monomers (i.e. amino acids) for ribosomal protein synthesis is rather limited to those alanine derivatives that are suitable for building α-helix or β-sheet secondary structural elements. Dominant secondary structures in life as we know it are α-helices and β-sheets and most canonical amino acids can be regarded as chemical derivatives of alanine. Therefore, most canonical amino acids in proteins can be exchanged with alanine by point mutations while the secondary structure remains intact. The fact that alanine mimics the secondary structure preferences of the majority of the encoded amino acids is practically exploited in alanine scanning mutagenesis. In addition, classical X-ray crystallography often employs the polyalanine-backbone model to determine three-dimensional structures of proteins using molecular replacement—a model-based phasing method.
=== Detergents, cosmetics, etc. === Sulfation is widely used in the production of consumer products such as detergents, shampoos, and cosmetics. Since the sulfate group is highly polar, its conjugation to a lipophilic "tail" gives surfacant-like properties. Well known sulfates are sodium lauryl sulfate and sodium laureth sulfate. Alkylsulfate are produced from alcohols by reaction with chlorosulfuric acid:
Sources: en.wikipedia.org
=== Trademark lawsuit against Nike === In July 2026, 7-Eleven filed a trademark infringement lawsuit against Nike, Inc. in the United States District Court for the Northern District of Texas, seeking to block the release of a new Nike Air Max 95 "Big Bubble" sneaker. The complaint alleged that the shoe's colorway imitated, in a "confusingly similar" manner, the orange, green, and red color combination of the 7-Eleven logo, which the company has used commercially since the 1980s and for which it holds multiple federal trademark registrations. 7-Eleven argued that the design could mislead consumers into believing that Nike had a partnership or collaboration with the company, noting that some product listings and media outlets had referred to the sneaker as the "7-Eleven" shoe or described it as "7-Eleven-inspired". The complaint also pointed to the shoe's planned release date of July 11, which coincides with the company's annual "7-Eleven Day" promotion, as evidence of deliberate association. 7-Eleven asked the court for a permanent injunction barring the sale and promotion of the shoe, a recall and destruction of existing inventory, disgorgement of profits, and damages. According to federal court records, Nike was served with the complaint on July 6, 2026; a hearing date had not yet been scheduled.
The history of fungaria is closely tied to the early development of botanical herbaria, the oldest of which date to the mid-1500s. Fungal fruiting bodies have been collected and deposited for several centuries, with millions of specimens accumulated chiefly to support fungal taxonomy. Early collections were often personal assemblages or teaching aids used to distinguish edible mushrooms from poisonous ones. Over time, fungal herbaria shifted from keeping one or a few representative specimens per taxon toward documenting developmental stages and geographic variation within species more broadly. In some regions, fungaria developed in close association with government plant-pathology programmes; in South Africa, for example, organised collecting expanded after the creation of a mycology post in 1905 and a separate Division of Plant Pathology and Mycology in 1910, whose early staff built the nucleus of the Pretoria herbarium. At the Royal Botanic Gardens, Kew, the mycological collection was established in the late 19th century after the donation of more than 10,000 fungal specimens by the mycologist Reverend Miles Joseph Berkeley. It was later enlarged through donations and collecting by staff and collaborators. More generally, fungaria were often built through a combination of personal collections, academic donations, and purchased exsiccatae series, drawing on wider networks of scientific exchange among mycologists.
===== Current studies ===== Four studies on different artificial pancreas systems are being conducted starting in 2017 and going into the near future. The projects are funded by the National Institute of Diabetes and Digestive and Kidney Diseases, and are the final part of testing the devices before applying for approval for use. Participants in the studies are able to live their lives at home while using the devices and being monitored remotely for safety, efficacy, and a number of other factors. The International Diabetes Closed-Loop trial, led by researchers from the University of Virginia, is testing a closed-loop system called inControl, which has a smartphone user interface. 240 people of ages 14 and up are participating for 6 months. A full-year trial led by researchers from the University of Cambridge started in May 2017 and has enrolled an estimated 150 participants of ages 6 to 18 years. The artificial pancreas system being studied uses a smartphone and has a low glucose feature to improve glucose level control. The International Diabetes Center in Minneapolis, Minnesota, in collaboration with Schneider Children's Medical Center of Israel, are planning a 6-month study that will begin in early 2019 and will involve 112 adolescents and young adults, ages 14 to 30. The main object of the study is to compare the current Medtronic 670G system to a new Medtronic-developed system. The new system has programming that aims to improve glucose control around mealtime, which is still a big challenge in the field.
Progesterone is the most important progestogen in the body. As a potent agonist of the nuclear progesterone receptor (nPR) (with an affinity of KD = 1 nM), the resulting effects on ribosomal transcription play a major role in regulation of female reproduction. In addition, progesterone is an agonist of the more recently discovered membrane progesterone receptors (mPRs), of which the expression has regulation effects in reproduction function (oocyte maturation, labor, and sperm motility) and cancer, although the roles are not yet well defined. Progesterone is also a ligand of the PGRMC1 (progesterone receptor membrane component 1) which impacts tumor progression, metabolic regulation, and viability control of nerve cells. Moreover, progesterone is also known to be an antagonist of the sigma σ1 receptor, a negative allosteric modulator of nicotinic acetylcholine receptors, and a potent antagonist of the mineralocorticoid receptor (MR). Progesterone prevents MR activation by binding to this receptor with an affinity exceeding even those of aldosterone, and glucocorticoids such as cortisol and corticosterone, and it produces antimineralocorticoid effects, such as natriuresis, at physiological concentrations. Progesterone also binds to, and behaves as a partial agonist of, the glucocorticoid receptor (GR), albeit with very low potency (EC50 >100-fold less relative to cortisol). Through its neurosteroid active metabolites, such as 5α-dihydroprogesterone and allopregnanolone, progesterone acts indirectly as a positive allosteric modulator of the GABAA receptor.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.